Lexicon Achieved Primary Efficacy Endpoint; Chelsea Announces Results from Northera Study Print E-mail
By Staff and Wire Reports   
Tuesday, 06 November 2012 20:22
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 6, 2012

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
announced data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.  

The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, lead investigator in the recently completed study.


Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP)
announced results from a study of Northera™ (droxidopa) in hypotensive individuals with spinal cord injury at the 23rd International Symposium on the Autonomic Nervous System, which took place October 31 through November 3, 2012 in Paradise Island, Bahamas.

The poster, titled "Blood Pressure Effect of Droxidopa in Hypotensive Individuals with Spinal Cord Injury," (poster #62) highlighted results of a clinical study designed to determine the blood pressure effect of escalating doses of droxidopa (100 mg, 200 mg & 400 mg) during three laboratory visits in hypotensive subjects (n=10) with spinal cord injury (SCI). The level of SCI ranged from cervical to low thoracic lesions, all were chronically injured and non-ambulatory and 8 were motor complete.

Subjects were hypotensive at baseline (systolic BP: 87±14 mmHg; diastolic BP: 54±8 mmHg), and baseline BP did not differ among the 3 visits. Upon supine repositioning prior to drug administration, BP increased significantly (SBP: 101±11 mmHg; DBP: 62±7 mmHg; p<0.0001 versus seated baseline), regardless of dose, droxidopa did not augment the increase in BP upon supine repositioning. Seated BP was significantly increased from baseline after droxidopa in a dose-dependent manner (100 mg: 94±14/61±8 mmHg; 200 mg: 99±15/62±9 mmHg; 400 mg: 106±16/58±9 mmHg; p<0.0001). Although the elevation in seated BP was relatively modest, average 4-hour seated SBP & DBP were significantly increased with 400 mg droxidopa compared to 100 mg (p<0.001) and 200 mg (p<0.05).

"These preliminary data indicate that droxidopa increases seated BP in a dose-dependent manner without worsening supine increases in BP in hypotensive persons with SCI, suggesting a greater normalization of pressure across positional changes," said lead author Jill M. Wecht, Ed.D, Associate Professor of Medicine and Rehabilitation Medicine, the Mount Sinai School of Medicine. "Increasing seated blood pressure is an important clinical outcome in these individuals, because hypotension has been linked to deficits in memory and attention processing in the general population and in individuals with SCI. Further study of droxidopa is warranted in the SCI population."

Also Tuesday:

Affymetrix, Inc. (NASDAQ:AFFX)
introduces Axiom® miRNA Target Site Genotyping Arrays, the only high-density genotyping tools for genome-wide evaluation of microRNA (miRNA) target sites.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
today announced that four abstracts containing new data on treatment with Feraheme® (ferumoxytol) Injection for intravenous (IV) use in patients with iron deficiency anemia with a history of unsatisfactory oral iron therapy will be presented at the 2012 Annual Meeting of the American Society of Hematology (ASH) taking place December 8-11, 2012 in Atlanta, Georgia.

Amarantus BioSciences, Inc. (OTCQB: AMBS)
, a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board.

today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

today reported financial and operating results for the third quarter and year-to-date period ended September 30, 2012.

Astro-Med, Inc. (NASDAQ: ALOT)
, a manufacturer of high tech specialty printers, test and measurement systems, and electronic medical instrumentation, will announce its financial results for the Third Quarter ended October 27, 2012 after the close of the market on November 20, 2012.

today announced that David Johnston, chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.m. (ET) in New York City.

Bio-Rad Laboratories, Inc. (NYSE: BIO)
and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2012.

Celsion Corporation (NASDAQ: CLSN)
, a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14th at 2:00 PM Eastern Time in New York City.

EnteroMedics Inc. (NASDAQ: ETRM)
, the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 1:00 pm Eastern Time at the Pierre Hotel in New York.

Given Imaging Ltd. (NASDAQ: GIVN)
today announced financial results for the third quarter ended September 30, 2012.

GTx, Inc. (Nasdaq: GTXI)
announced today that management will present a company overview on November 13, 2012 at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City.

Halozyme Therapeutics, Inc. (NASDAQ: HALO)
will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference in New York on Tuesday, November 13, 2012 at 1:30 p.m. PT/4:30 p.m. ET.Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

is pleased to announce that on October 26, 2012, the Company, in cooperation with HPIL Real Estate Inc., a wholly owned subsidiary of the Company, entered in a certain Quota Purchase Agreement for the acquisition of 32% of Haesler Real Estate Management, a real estate management company organized in Switzerland.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)
, a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, November 8, 2012 at 8:30 a.m. EST to discuss results for the third quarter ended September 30, 2012 and a business outlook for the remainder of 2012.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
, a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2012.

Nektar Therapeutics (Nasdaq: NKTR)
will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012, after the close of U.S.-based financial markets.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Lazard Capital Market's 9th Annual Healthcare Conference in New York.

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio)
a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has initiated a collaboration with Sarah Cannon Research UK and the Leaders in Oncology Care (LOC) on a Phase I/II trial with DCVax®-Direct for metastatic colon cancer.  

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)
announced today the completion of patient enrollment in the primary registration Phase 3 study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer.

PacificHealth Laboratories, Inc. (OTCQB: PHLI) (OTCBB: PHLI)
, a leading sports nutrition company, today reported its financial results for the quarter and nine months ended September 30, 2012.

PharmAthene, Inc. (NYSE Amex: PIP)
, a biodefense company developing medical countermeasures against biologicaland chemical threats, today reported its financial results for the third quarter ended September 30, 2012.

Rosetta Genomics (NASDAQ: ROSG)
, a leading developer and provider of microRNA-based molecular diagnostic assays, announces that the New York State Department of Health has given the Company final approval for its miRview® lung assay following conditional approval issued in June 2012.

Sangamo BioSciences, Inc. (Nasdaq: SGMO)
announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic®development programs and an overview of the company's business strategy at 3:30 pm ET on Tuesday, November 13, 2012, at the Lazard Capital Markets 9th Annual Healthcare Conference which will be held in New York City.

Sequenom, Inc. (NASDAQ: SQNM)
, a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference in New York and the Jefferies 2012 Global Healthcare Conference in London.  

Sionix Corporation (OTCQB: SINX)
provided an update today on its Madava Farms - Crown Maple Project in New York. In accordance with its contractual obligations, Sionix personnel recently completed the integration of Sionix technology with the key systems of the Madava Farms syruping process as well as successful onsite testing of the Maple Sap Filtration Unit ("MSFU").

Stevia First Corp.(OTCBB: STVF)
("Stevia First" or the "Company"), an early-stage agribusiness based in California's Central Valley growing region and focused on the industrial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, today announced it has launched a full suite of social media tools aimed at improving the Company's ability to reach and engage with its growing audience of followers.

WuXi PharmaTech (Cayman) Inc. (NYSE: WX)
today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 6, 2012.

YarcData, a Cray (NASDAQ: CRAY) company dedicated to providing "Big Data" graph-analytic solutions to enterprise customers, today announced it was awarded a contract to deliver a uRiKA graph-analytics appliance to the Oak Ridge National Laboratory (ORNL).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus